Minireviews
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 28, 2020; 26(16): 1901-1911
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1901
Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
Hui-Ting Chen, Hong-Li Huang, Yong-Qiang Li, Hao-Ming Xu, Yong-Jian Zhou
Hui-Ting Chen, Hong-Li Huang, Yong-Qiang Li, Hao-Ming Xu, Yong-Jian Zhou, Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, Guangdong Province, China
Hui-Ting Chen, Hong-Li Huang, Yong-Qiang Li, Hao-Ming Xu, Yong-Jian Zhou, Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou 510180, Guangdong Province, China
Author contributions: Chen HT performed the majority of the writing; Huang HL performed data acquisition and writing; Li YQ and Xu HM prepared the figure and table and coordinated the writing of the paper; Zhou YJ organized the interpretation of the data and revision of the article.
Supported by Guangzhou General Science and Technology Project of Health and Family Planning, No. 20191A011001; Guangzhou Planned Project of Science and Technology, No. 201904010132.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yong-Jian Zhou, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Guangzhou Institute of Digestive Disease, Guangzhou Medical University, No. 1, Panfu Road, Guangzhou 510180, Guangdong Province, China. yjzhou@gzhmu.edu.cn
Received: December 31, 2019
Peer-review started: December 31, 2019
First decision: January 13, 2020
Revised: March 26, 2020
Accepted: April 4, 2020
Article in press: April 4, 2020
Published online: April 28, 2020
Core Tip

Core tip: Non-alcoholic fatty liver disease is a highly prevalent metabolic disease worldwide. In this review, we summarize the most recent advances in gut microbiota-targeted therapies against non-alcoholic fatty liver disease, including antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and the gut microbiota-derived components and metabolites.